《大行》摩通升信达生物(01801.HK)目标价至55元 料今年IFRS层面扭亏为盈

阿斯达克财经
31 Mar

摩根大通发表研究报告指,信达生物(01801.HK) 2024年业绩表现出色,许可费收入胜过市场预期,按年增长146%,并通过提升效率和成本控制措施,成功提升毛利率及降低经营开支比,首次实现非国际财报准则(non-IFRS)下的经调整净利润及正数EBITDA,是公司发展的里程碑。

因此摩通亦上调其产品销售预测,憧憬该公司可于2025年录得国际财报准则(IFRS)净利润,即实现扭亏,将进一步提振市场信心,目标价从50元上调至55元,维持“增持”评级。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-31 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10